Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review

Coronavirus disease-2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multiorgan manifestations. Lipid-modulating agents may be useful in treating patients with COVID-19. These agents may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory...

Descripción completa

Detalles Bibliográficos
Autores principales: Talasaz, Azita H., Sadeghipour, Parham, Aghakouchakzadeh, Maryam, Dreyfus, Isaac, Kakavand, Hessam, Ariannejad, Hamid, Gupta, Aakriti, Madhavan, Mahesh V., Van Tassell, Benjamin W., Jimenez, David, Monreal, Manuel, Vaduganathan, Muthiah, Fanikos, John, Dixon, Dave L., Piazza, Gregory, Parikh, Sahil A., Bhatt, Deepak L., Lip, Gregory Y.H., Stone, Gregg W., Krumholz, Harlan M., Libby, Peter, Goldhaber, Samuel Z., Bikdeli, Behnood
Formato: Online Artículo Texto
Lenguaje:English
Publicado: by the American College of Cardiology Foundation. Published by Elsevier. 2021
Materias:
The Present and Future
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504484/
https://www.ncbi.nlm.nih.gov/pubmed/34649702
http://dx.doi.org/10.1016/j.jacc.2021.08.021
Descripción
Sumario:Coronavirus disease-2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multiorgan manifestations. Lipid-modulating agents may be useful in treating patients with COVID-19. These agents may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglyceride levels portend worse outcomes in patients with COVID-19. Upon a systematic search, 40 randomized controlled trials (RCTs) with lipid-modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrate RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for the management or prevention of COVID-19. From these 40 RCTs, only 2 have reported preliminary results, and most others are ongoing. This paper summarizes the ongoing or completed RCTs of lipid-modulating agents in COVID-19 and the implications of these trials for patient management.

Ejemplares similares